View source for 20240052039. PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION simplified abstract (Fundação Oswaldo Cruz)

=PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION=


==Organization Name==

[[:Category:Fundação Oswaldo Cruz|Fundação Oswaldo Cruz]]


[[Category:Fundação Oswaldo Cruz]]

==Inventor(s)==

[[:Category:Vinicius Cotta de Almeida of Rio de Janeiro (BR)|Vinicius Cotta de Almeida of Rio de Janeiro (BR)]][[Category:Vinicius Cotta de Almeida of Rio de Janeiro (BR)]]

[[:Category:Beatriz Chaves of Fortaleza (BR)|Beatriz Chaves of Fortaleza (BR)]][[Category:Beatriz Chaves of Fortaleza (BR)]]

[[:Category:Carolina Lessa Aquino of Rio de Janeiro (BR)|Carolina Lessa Aquino of Rio de Janeiro (BR)]][[Category:Carolina Lessa Aquino of Rio de Janeiro (BR)]]

[[:Category:João Hermínio Martins Da Silva of Fortaleza (BR)|João Hermínio Martins Da Silva of Fortaleza (BR)]][[Category:João Hermínio Martins Da Silva of Fortaleza (BR)]]

[[:Category:Marco Alberto Medeiros of Rio de Janeiro (BR)|Marco Alberto Medeiros of Rio de Janeiro (BR)]][[Category:Marco Alberto Medeiros of Rio de Janeiro (BR)]]

[[:Category:Wilson Savino of Niterói (BR)|Wilson Savino of Niterói (BR)]][[Category:Wilson Savino of Niterói (BR)]]

[[:Category:Ingo Riederer of Rio de Janeiro (BR)|Ingo Riederer of Rio de Janeiro (BR)]][[Category:Ingo Riederer of Rio de Janeiro (BR)]]

==PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240052039 titled 'PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION

==Simplified Explanation==

The present invention is a protein of the scfv type, consisting of a first polypeptide chain and a second polypeptide chain joined by a ligand. The protein has the formula (VH domain)-(ligand)-(VL domain). 

The invention also includes a polynucleotide with a specific nucleotide sequence, a vector containing the polynucleotide, and a host cell containing the vector. Additionally, a composition comprising the protein and a pharmaceutically acceptable excipient is provided.

The invention further relates to a method for treating a disease or condition resulting from α4β1 integrin activity, as well as an in vitro method for prognosing multiple sclerosis. The protein or composition defined above can be used in the manufacture of a drug for the treatment of multiple sclerosis.

* The invention is a protein of the scfv type, consisting of two polypeptide chains joined by a ligand.
* A specific nucleotide sequence and vector containing it are also part of the invention.
* The invention provides a method for treating diseases related to α4β1 integrin activity.
* It also includes an in vitro method for prognosing multiple sclerosis.
* The protein or composition can be used in the manufacture of a drug for the treatment of multiple sclerosis.

== Potential Applications ==
This technology has potential applications in the field of pharmaceuticals and biotechnology. It can be used for the development of drugs for the treatment of diseases related to α4β1 integrin activity, particularly multiple sclerosis. The protein and composition described in the patent application can be utilized in the manufacturing process of these drugs.

== Problems Solved ==
This technology addresses the need for effective treatments for diseases or conditions resulting from α4β1 integrin activity. It specifically focuses on multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. By targeting α4β1 integrin activity, the invention aims to provide a solution for managing the symptoms and progression of multiple sclerosis.

== Benefits ==
The use of the protein or composition described in the patent application offers several benefits. It provides a targeted approach for treating diseases related to α4β1 integrin activity, potentially improving patient outcomes. The invention also introduces an in vitro method for prognosing multiple sclerosis, allowing for earlier detection and intervention. Overall, this technology has the potential to advance the field of multiple sclerosis treatment and diagnosis.


==Original Abstract Submitted==

the present invention relates to a protein of the scfv type in which said protein comprises a first polypeptide chain and a second polypeptide chain joined by a ligand, having the formula as follows: (vh domain)-(ligand)-(vl domain). the present invention further relates to a polynucleotide comprising the nucleotide sequence shown in seq id no: 1; to a vector comprising the polynucleotide as defined above; to the host cell comprising the vector as previously defined; and the composition comprising the aforementioned protein and a pharmaceutically acceptable excipient. the present invention further relates to a method for treating a disease or condition that results directly or indirectly from �4�1 integrin activity. the present invention further relates to an in vitro method for prognosing multiple sclerosis. the present invention further relates to the use of the previously defined protein or composition in the manufacture of a drug for the treatment of multiple sclerosis.



[[Category:C07K16/28]]
[[Category:G01N33/68]]